Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
24 Mayo 2024 - 5:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 23 May 2024, London UK
Statement: Zantac (ranitidine) litigation - Valadez and Williams
cases
●
Jury in Valadez case in Illinois state
court finds GSK not liable for plaintiff's colorectal
cancer
●
Verdict is consistent with scientific
consensus that there is no consistent or reliable evidence that
ranitidine increases the risk of any cancer
●
GSK
will continue to vigorously defend itself against all other
claims
●
Next
Zantac trial (Williams) due to start in Illinois
dismissed
GSK plc (LSE/NYSE: GSK) welcomes
today's jury verdict in the Valadez case in Illinois state court
finding in GSK's favour in the first Zantac case to go to trial.
This outcome is consistent with the scientific consensus that there
is no consistent or reliable evidence that ranitidine increases the
risk of any cancer, supported by 16 epidemiological studies looking
at human data regarding the use of ranitidine. GSK will continue to
vigorously defend itself against all other
claims.
Prior to this verdict, the court rejected the Plaintiff's ability
to request punitive damages.
Separately, the company welcomed the recent court ruling dismissing
the next Zantac trial (Williams) that was due to start on 23 May
2024. In the Williams case, the Illinois state court dismissed the
case before trial on the basis that GSK was not the brand
manufacturer of over-the-counter Zantac at the time the Plaintiff
allegedly used it and should not be liable for any subsequent
over-the-counter Zantac use.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q1 Results for 2024.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
24, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
GSK (NYSE:GSK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
